These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36509369)

  • 1. Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: The Case of Switching to High-Dose Influenza Vaccine for Dutch Older Adults.
    Zeevat F; Wilschut JC; Boersma C; Postma MJ
    Value Health; 2023 Apr; 26(4):461-464. PubMed ID: 36509369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial.
    Hollingsworth R; Palmu A; Pepin S; Dupuy M; Shrestha A; Jokinen J; Syrjänen R; Nealon J; Samson S; De Bruijn I
    Am Heart J; 2021 Jul; 237():54-61. PubMed ID: 33722585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.
    Chen JY; Hsieh SM; Hwang SJ; Liu CS; Li X; Fournier M; Yeh TY; Yin JK; Samson SI
    Vaccine; 2022 Oct; 40(45):6450-6454. PubMed ID: 36216650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.
    Kohli MA; Maschio M; Mould-Quevedo JF; Drummond M; Weinstein MC
    Hum Vaccin Immunother; 2021 Nov; 17(11):4603-4610. PubMed ID: 34550848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay.
    Arbo A; Martinez-Cuellar C; Vazquez C; Bellier L; Adorno C; Dibarboure H; Lopez JG; Petitjean A; Bianculli P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2069974. PubMed ID: 35543602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Vaccination of Older Adults with an MF59
    Jacob J; Biering-Sørensen T; Holger Ehlers L; Edwards CH; Mohn KG; Nilsson A; Hjelmgren J; Ma W; Sharma Y; Ciglia E; Mould-Quevedo J
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany.
    Molnar D; Anastassopoulou A; Poulsen Nautrup B; Schmidt-Ott R; Eichner M; Schwehm M; Dos Santos G; Ultsch B; Bekkat-Berkani R; von Krempelhuber A; Van Vlaenderen I; Van Bellinghen LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2058304. PubMed ID: 35486410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Redondo E; Drago G; López-Belmonte JL; Guillén JM; Bricout H; Alvarez FP; Callejo D; Gil de Miguel Á
    Vaccine; 2021 Aug; 39(36):5138-5145. PubMed ID: 34344553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
    BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.
    Amiche A; Tanriover MD; Bellier L; Ugur B; Akin L
    Value Health Reg Issues; 2021 Sep; 25():15-22. PubMed ID: 33485248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM; Bellier L; Mangado IO; Pérez CG; Mieres G; Lazarov L; Petitjean A; Dibarboure H; Lopez JG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2050653. PubMed ID: 35344679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain.
    Ruiz-Aragón J; Márquez-Peláez S; Gani R; Alvarez P; Guerrero-Luduena R
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
    [No Abstract]   [Full Text] [Related]  

  • 17. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Gärtner BC; Weinke T; Wahle K; Kwetkat A; Beier D; Schmidt KJ; Schwarz TF
    Vaccine; 2022 May; 40(22):2999-3008. PubMed ID: 35459556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults.
    Loong D; Pham B; Amiri M; Saunders H; Mishra S; Radhakrishnan A; Rodrigues M; Yeung MW; Muller MP; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Aug; 25(8):1439-1458. PubMed ID: 35659487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Bellier L; Petitjean A; Sarazu T; Tresierra J; Lopez JG
    Vaccine; 2021 Jul; 39(30):4144-4152. PubMed ID: 34130885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
    Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
    PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.